Dalacin, gel 1% 30 g

Dalacin is an antibiotic of lincosamide group for topical use.

The mechanism of action is associated with inhibition of protein synthesis in the microbial cell through interaction with the 50S-subunit of ribosomes.

It has bacteriostatic action; in higher concentrations against some microorganisms it is bactericidal.

Indications

Vulgar blackheads.

Active ingredient

Composition

1 g of the gel contains clindamycin (in the form of clindamycin phosphate) – 10 mg;

insupplements:

allantoin;

methylparaben;

propylene glycol;

polyethylene glycol;

carbomer 934P;

sodium hydroxide;

purified water

How to take, the dosage

A thin layer of gel is applied to the affected skin area, previously cleaned and dry, twice a day.

Course of treatment: For satisfactory results, therapy should be continued for 6 to 8 weeks, and if necessary may be continued for up to 6 months.

Interaction

An antagonistic interaction between clindamycin and erythromycin has been demonstrated under in vitro conditions.

It has been found that when used systemically, clindamycin impairs neuromuscular transmission, so the effect of peripheral myorelaxants may be enhanced. This fact should be taken into account when prescribing the latter with Dalacin.

In pharmacodynamic, pharmacokinetic or clinical studies of these dosage forms no interactions have been observed.

Special Instructions

When using clindamycin systemically it is possible to develop severe diarrhea and in some cases pseudomembranous colitis.

In this regard, in case of severe or prolonged diarrhea during therapy with Dalacin the drug should be discontinued, diagnostic procedures should be performed and if necessary appropriate treatment should be prescribed.

Contraindications

Hypersensitivity to clindamycin, lincomycin or any component of Dalacin.

Side effects

The incidence of the following side effects is less than 10%.

In the genital system: irritation of the mucous membrane of the vulva and the vagina, vaginal pain, vaginal discharge, vaginal candidiasis, vulvovaginitis, trichomonas vaginitis, vaginal infections, menstrual disorders, uterine bleeding, abnormal labor, endometriosis.

Urinary system disorders: dysuria, urinary tract infections (including pyelonephritis), proteinuria.

Digestive system disorders: generalized abdominal pain, localized abdominal pain, abdominal cramps, abdominal distension, dyspepsia, nausea, vomiting, diarrhea, constipation, flatulence, bad breath, perversion of taste.

CNS side: dizziness, headache.

Dermatological reactions: rash, itching, maculopapular rash, erythema, candidiasis of the skin.

Allergic reactions: urticaria.

Endocrine system disorders: glucosuria, hyperthyroidism.

Allergic reactions: fungal infections, fever, flank pain, back pain, abdominal pain, generalized pain, bacterial infections, inflammatory edema, upper respiratory tract infections, nasal bleeding, abnormal results of microbiological tests.

Local reactions: itching and pain at the injection site.

Overdose

In intravaginal use clindamycin may be absorbed in amounts sufficient to cause systemic reactions.

Inadvertent ingestion may also cause systemic effects similar to those occurring after oral administration of clindamycin in therapeutic doses. Possible systemic side effects include diarrhea, hemorrhagic diarrhea, including pseudomembranous colitis.

Treatment: if necessary, symptomatic and supportive therapy is carried out.

Pregnancy use

Adequate and controlled studies on the use of the drug in the first trimester of pregnancy have not been conducted. The use of Dalacin in the first trimester of pregnancy is possible only if the estimated benefit exceeds the potential risk to the fetus.

When clindamycin preparations are used in the second and third trimesters of pregnancy in intravaginal dosage forms, no increase in the incidence of fetal congenital abnormalities has been reported. If Dalacin is used in the second and third trimesters of pregnancy (although there have been no official studies on the use of suppositories in pregnancy), adverse effects on the fetus seem unlikely.

There are currently no data on the excretion of clindamycin with breast milk during intravaginal use of Dalacin. However, it has been found that when clindamycin is administered orally or parenterally, some amount is detected in breast milk.

Therefore, when deciding whether to prescribe Dalacin during lactation (breastfeeding), the expected benefit to the mother and the possible risk to the baby should be compared.

Similarities